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Abstract
Glial cell line-derived neurotrophic factor (GDNF) promotes development and differentiation of dopaminergic neurons, thus
it has an important role in dopamine-related neuropsychiatric disorders. Since the role of dopamine system in smoking is
well established, we hypothesized that GDNF gene variants may affect smoking behaviour. Self-reported data on smoking
behaviour (never smoked, quit, occasional, or regular smokers) and level of nicotine addiction (Hooked on Nicotine Checklist
and Fagerstrom Nicotine Addiction Scale), anxiety, as well as buccal samples were obtained from 930 Hungarian young
adults (18–35 years). Genetic analysis involved eight GDNF single-nucleotide polymorphisms (SNP) (rs1981844, rs3812047,
rs3096140, rs2973041, rs2910702, rs1549250, rs2973050 and rs11111). Allele-wise association analyses of the eight GDNF
SNPs provided a signiﬁcant association between smoking behaviour and rs3096140 (P = 0.0039). The minor allele (C) was
more frequent in those groups who smoked in some form (quit, occasional or regular smokers) as compared to those who never
smoked (P = 0.0046). This result remained signiﬁcant after Bonferroni correction for multiple testing. In the ever smoking
group, no signiﬁcant differences were found in the level of nicotine addiction by the alleles of these polymorphisms. Also, no
signiﬁcant interaction of rs3096140 and smoking categories were observed on anxiety mean scores. Although previous data
demonstrated an association between GDNF rs2910704 and severity of methamphetamine use to the best of our knowledge,
this is the ﬁrst study on the role of GDNF genetic variations in smoking behaviour. Our results suggest that GDNF rs3096140
might be involved in the genetic background of smoking, independent of anxiety characteristics.
[Kotyuk E., Nemeth N., Ronai Z., Demetrovics Z., Sasvari-Szekely M. and Szekely A. 2016 Association between smoking behaviour and
genetic variants of glial cell line-derived neurotrophic factor. J. Genet. 95, 811–818]
Introduction
Recent genomewide association studies successfully identi-
ﬁed some genetic markers of smoking. In a meta-analyses of
genomewide association studies of smoking behaviour, the
Tobacco and Genetics Consortium has found a gene vari-
ant in the chromosome-15 nicotinic acetylcholine receptor
gene (CHRNA3 rs1051730) to be associated with the number
of cigarettes smoked per day (Tobacco and Genetics 2010),
replicating earlier results (Berrettini et al. 2008; Thorgeirsson
et al. 2008). They found some further SNPs associated at
a genomewide signiﬁcance level with cigarettes per day on
this large sample, and a BDNF gene polymorphism (rs6265)
∗For correspondence. E-mail: kotyeszter@gmail.com.
associated with smoking initiation. These associations seem
to be reliable and replicable, however, they only explain a
small per cent of the highly heritable smoking behaviour phe-
notypes (Sullivan and Kendler 1999; Li et al. 2003). Thus,
further targeted genetic association analyses based on earlier
genetic association studies and results from animal models
suggesting a reliable association are needed. According to
a well-established psychopharmacological hypothesis (Dani
and Heinemann 1996) reward mechanisms have crucial
role in reinforcement of addictions. Neurobiological stud-
ies demonstrated that nicotine intake during smoking effects
primarily the mesolimbic dopamine neurons by activa-
tion and desensitization of mesolimbic nicotine receptors
(Pidoplichko et al. 1997). Moreover, various dysfunctions
in dopamine neurotransmission were shown to increase the
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risk of nicotine addiction (Pontieri et al. 1996). Based on
these studies, the dopamine system has a key role in various
addictions, including smoking.
GDNF gene codes the glial cell line-derived neurotrophic
factor (GDNF) (Lin et al. 1993), a trophic factor for
dopaminergic neurons. The main function of GDNF is to pro-
mote the development and differentiation of dopaminergic
neurons (Hudson et al. 1995; Granholm et al. 2000), and it is
an important neuroprotective element of midbrain dopamin-
ergic neurons (Nitta et al. 2004). Dopamine dysfunctions are
present in Parkinson disease and the early pharmacological
studies of GDNF provides promising results about applica-
tion of GDNF in the treatment of the disease (Gill et al. 2003;
Lang et al. 2006).
It has been demonstrated that mice lacking one of the
GDNF alleles (GDNF+/−) can be characterized by a lower
striatal GDNF protein level than their wild-type littermates
(Airavaara et al. 2004) and had an augmented reward,
because increased GDNF levels attenuated the reward pro-
cesses (Grifﬁn et al. 2006). It has also been shown that
reduction in the expression of GDNF gene potentiated
methamphetamine self-administration, enhanced motivation
to take methamphetamine, increased vulnerability to drug-
primed reinstatement, and prolonged cue-induced reinstate-
ment of extinguished methamphetamine seeking behaviour
(Yan et al. 2007). Moreover, it has been shown that GDNF
infusion into the ventral tegmental area (VTA) blocks both
the adaptation for chronic cocaine or morphine intake and
the rewarding effects of cocaine. In line with these ﬁnd-
ings, the intraVTA infusion of antiGDNF antibody enhanced
responses to cocaine in rats with heterozygous null muta-
tion in GDNF gene (Messer et al. 2000). Based on these
observations, GDNF pathways of the VTA must be involved
in the mechanism of drug abuse. There are promising
results on possible application of GDNF for the treat-
ment of drug dependence. In an animal study, hydrophobic
dipeptide Leu-Ile was administered to the animals; Leu-Ile
protects against neuronal death by inducing brain-derived
neurotrophic factor and GDNF. They found that pretreatment
with Leu-Ile blocked the acquisition of methamphetamine
induced place preference and sensitization, while posttreat-
ment with Leu-Ile attenuated them even after the develop-
ment of methamphetamine-induced rewarding effects and
sensitization (Niwa et al. 2007). Further, association analyses
of GDNF polymorphisms have revealed an effect of GDNF
polymorphism on methamphetamine use (Yoshimura et al.
2011). It has also been proposed that the high comorbidity
of mood disorders and addictions may be due to overlapping
neurological or genetic factors (Kendler et al. 1993; Lyons et
al. 2008). In line with this hypothesis, we previously demon-
strated an association between GDNF polymorphisms and
mood characteristics on healthy sample (Kotyuk et al. 2013a)
and on patients with bipolar or major depression (Kotyuk
et al. 2013b). In the present study, we raised the question
if GDNF polymorphisms play a role in smoking behaviour
and nicotine addiction assessed by the Hooked on Nicotine
Checklist (HONC) and the Fagerstrom Nicotine Dependence
(FTND) scale in a sample of healthy young adults.
Materials and methods
Sample
Thousand two hundred and twenty-two independent Cau-
casian (Hungarian) young adults from several Hungarian
education facilities were involved in the study on a volun-
tary basis. The study protocol was designed in accordance
with the guidelines of the Declaration of Helsinki, and was
approved by the Scientiﬁc and Research Ethics Committee
of the Medical Research Council (ETT TUKEB). The par-
ticipants signed a written informed consent, provided buc-
cal samples and ﬁlled questionnaire on their smoking habits.
The selection criteria included no previous history of depres-
sion, diabetes or any psychiatric illness, age range between
18 and 35 years, and nonrelated participants (all based on
self-report). Participants with invalid self-report data for the
smoking habit questionnaire were also excluded. Of the 1066
potential participants, 42 had previous psychiatric illness or
were from high risk populations (e.g. reformatory facilities),
15 were excluded because their family members have already
participated in the study, ﬁve provided invalid answers for
the smoking habit questionnaire and 74 participants were
excluded because data was missing on their smoking habits.
Finally, 930 participants’ data were analysed (44.2% males,
55.8% females; mean age: 21.3 ± 2.9 years). Genotypic and
phenotypic data of the present study is publicly available
through the NCBI dbGaP data repository: http://www.ncbi.
nlm.nih.gov/gap.
Phenotype measures
The questions contained in the questionnaire were about age,
gender, previous psychiatric illness and smoking habits. The
smoking habit questionnaire contained 27 questions. The
ﬁrst four questions were about the frequency of smoking
and previous attempts of quitting. Further questions con-
tained the HONC (DiFranza et al. 2002; Urbán et al. 2004)
questionnaire and the FTND (Heatherton et al. 1991;
Urbán et al. 2004). The nicotine dependence scales (both
HONC and FTND scales) were ﬁlled only by regular and
occasional smokers. To increase reliability, we only calcu-
lated the values of these scales if the answers for the previous
four questions were coherent, therefore, we excluded contro-
versial answers. Further, values of the scales were only calcu-
lated if at least 70% of the scale’s items were answered. This
criteria narrowed the regular and occasional smokers sample
from 348 to 334 for the HONC and 212 for the FTND scales.
Level of anxiety and depression have been assessed by the
Hungarian version (Muszbek et al. 2006) of hospital anx-
iety and depression scale (Zigmond and Snaith 1983), as
described elsewhere (Kotyuk et al. 2013a).
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Sample preparation and SNP genotyping
The SNP selection criteria, the sample preparation and SNP
genotyping are described in details elsewhere (Kotyuk et al.
2013a). Brieﬂy, a proper coverage of GDNF gene was
ensured by selection of tagging SNPs from HapMap data
using a pairwise tagging method. SNPs referred in previous
association studies were prioritized. Concentration of iso-
lated DNA was measured by an intercalation assay. Genotyp-
ing was carried out by the TaqMan OpenArray genotyping
system of Applied Biosystems using sequence-speciﬁc, ﬂu-
orescent TaqMan probes and a miniaturized PCR system
working with nanoliter scale sample volume. Raw data
obtained by end-point (postPCR) detection were evaluated
by the TaqMan Genotyper v1.2 software. DNA samples,
2% were measured in duplicates, showing higher than 98%
reproducibility. Linkage disequilibrium of the studied GDNF
polymorphisms is described elsewhere (Kotyuk et al. 2013a).
Overall, the studied SNPs are in low to high linkage in
the present sample. Based on the Lewontin’s D′ measure,
one linkage block has been identiﬁed among rs1549250,
rs2910702 and rs2973041. Although, no functional data is
available on the SNPs studied here, it is important to note
that rs3096140 SNP is in the close proximity of critical sites
of alternative splicing.
Statistical analysis
Statistical analyses were carried out in SPSS 20.0 for Win-
dows to test the gender differences in nicotine addiction inde-
pendent samples. Pearson correlations were carried out to test
the relationship between age and nicotine addiction. To anal-
yse the relationship between HONC and FTND, Pearson’s
correlation analysis was used. Possible gender differences in
the genotype distributions and Hardy–Weinberg equilibrium
(HWE) of genotype frequencies were tested with chi-square
(χ2) analyses. Chi-square analyses were also used for the
case–control association analyses testing allele distribution
differences in the four smoking categories. One-way analy-
ses of covariance (ANCOVA) were used for the dimensional
analyses testing the differences in the mean dependence
scores of HONC and FTND of carriers of the different alle-
les (with gender as a covariant variable). All the association
analyses were carried out in an allele-wise model. The pos-
sible false positive associations were ruled out by correcting
for multiple testing. Bonferroni correction (Bonferroni 1936;
Miller 1981) has been applied with a corrected level of sig-
niﬁcance of 0.00625 (0.05/8 = 0.00625) as the nominal P
(value 0.05) was divided by the number of SNPs tested (eight).
Results
Descriptive data and reliability of the measured phenotypes
and genotypes
Based on the ﬁrst four self-report questions about the partici-
pants’ smoking habits, we created four categories of smoking
behaviour: never smoked, those who already quit smoking,
occasional smokers and regular smokers. From the 930
participants, 494 were never smoked (53.1%), 88 partici-
pants have already quit smoking (9.5%), 163 participants
were occasional smokers (17.5%), and 185 regular smok-
ers (19.9%). These seem to be in line with the results from
other studies (Bogdanovica et al. 2011) indicating that the
present sample is in agreement with the Hungarian popula-
tion’s smoking habits. Based on our questionnaire data, on
average, participants of the present sample started to smoke
at the age of 16 and have been smoking for 4–5 years. Cron-
bach’s alpha values were calculated for HONC and FTND
to test the internal consistency on the subsamples of smokers
(either regular or occasional). The Cronbach’s alpha values
were satisfactory for both HONC (0.843) and FTND (0.646).
The HONC scale had a mean value of 4.624 (±3.2) with indi-
vidual scores ranging from 0 to 13 (HONC mean value was
2.64 ± 2.6 for occasional smokers, and 6.31 ± 2.8 for reg-
ular smokers). The item means were between 0.05 and 0.72
based on 638 participants’ answers. The FTND scale had a
mean value of 1.188 (±1.4) and the individual scores ranged
between 0 and 6 (FTND mean value was 0.43 ± 0.9 for occa-
sional smokers and 1.36 ± 1.6 for regular smokers). The item
means were between 0.08 and 0.31 based on the 426 partic-
ipants’ answers. The intercorrelation of the two scales was
tested with Pearson’s correlation. The two scales were in a
Table 1. Genotype distribution of the studied GDNF
polymorphisms.
dbSNP
number Genotype N Per cent HWE Call rate (%)
rs1981844 GG 402 54.6 P = 0.988 75
CG 285 38.7
CC 49 6.7
rs3812047 GG 673 76.5 P = 0.401 87
GA 188 21.4
AA 19 2.2
rs3096140 TT 435 47.6 P = 0.999 91
TC 390 42.7
CC 88 9.6
rs2973041 AA 512 70.6 P = 0.721 72
AG 191 26.3
GG 22 3.0
rs2910702 AA 400 54.2 P = 0.947 73
GA 289 39.2
GG 49 6.6
rs1549250 TT 243 32.6 P = 0.996 74
TG 366 49.1
GG 136 18.3
rs2973050 CC 249 40.8 P = 0.495 61
TC 292 47.9
TT 69 11.3
rs11111 AA 669 75.8 P = 0.718 88
AG 196 22.2
GG 18 2.0
dbSNP number, polymorphism identiﬁcation number in an open-
access archive made by the National Center for Biotechnology
Information (NCBI) and National Human Genome Research Insti-
tute (NHGRI); HWE, Hardy–Weinberg equilibrium.
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signiﬁcant moderate correlation: r = 0.449 (P < 0.001).
HWE was tested to check if there were any signiﬁcant dif-
ference between the distributions of observed and calculated
genotype frequencies. As shown in table 1, genotypes of all
the eight SNPs were in HWE.
Age and sex as possible confounds
The possible age and gender effects on the phenotypes were
tested. Age and gender differences by the four smoking cate-
gories were tested ﬁrst. There were no signiﬁcant difference
in the frequency of males and females in the four smoking
categories, however, there was a signiﬁcant age difference in
smoking habits (F(3, 926) = 4.084; P = 0.007). The results
showed that 88 participants who quit smoking have the high-
est mean age (22.16 ± 3.5), followed by the regular smok-
ers (21.62 ± 2.6), the never smokers (21.20 ± 3.0) and the
occasional smokers (20.99 ± 2.6). We also tested the gender
differences on both scales with independent samples t-tests.
No signiﬁcant differences were observed by genders in case
of the HONC scale (t(628) = −0.278; P = 0.981). How-
ever, in case of FTND scale, we found a signiﬁcant gender
effect: t(422) = 3.006; P = 0.003. In average, the males had
higher nicotine dependence (1.41 ± 0.1) measured by the
FTND than female participants (0.99 ± 1.4). We tested with
Pearson’s correlation the relationship between the age and
both nicotine addiction scales. There was no signiﬁcant cor-
relation between age and HONC (r = 0.049; P = 0.206), nor
between age and FTND (r = −0.018; P = 0.708). The pos-
sible gender differences in the genotype distribution of the
polymorphisms were also tested: no signiﬁcant differences
were found based on χ2 analyses. Analysis of the possible
age difference in genotypic distribution has been tested by
using one sample variance analysis. A signiﬁcant mean age
difference was found in the genotypes of rs11111 (F(2, 818) =
3.055; P = 0.048). There was also a signiﬁcant difference
by mean age in case of rs3096140 (F(2, 846) = 3.996; P =
0.019). The other polymorphisms did not show signiﬁcant
associations with age. Based on these results, we used age
and gender as covariates in the genetic association analyses.
Case–control analyses of smoking behaviour and GDNF
polymorphisms
First, distributions of allele frequencies among never smok-
ers and ever smokers have been tested in accordance with the
standard genetic-epidemiological form of addictions in terms
of lifetime occurrence of smoking behaviour (Madden et al.
1999, 2004; Maes et al. 2004). In these 2 × 2 χ2 analyses,
Table 2. Case–control analysis: allele distribution in various smoking categories.
Ever smoker-lifetime vulnerability
dbSNP Never Quit Occasional Regular
number Allele 2*N MAF (2*N = 988) (2*N = 176) (2*N = 326) (2*N = 370)
rs1981844 C 366 0.264 27.7% 25.0% 24.8% 24.8%
G 1020 72.3% 75.0% 75.2% 75.2%
χ2 = 1.495 df=1 P = 0.221; χ2 = 1.497 df = 3 P = 0.683
rs3812047 A 204 0.126 12.8% 15.2% 11.6% 11.6%
G 1418 87.2% 84.8% 88.4% 88.4%
χ2 = 0.076 df = 1 P = 0.783; χ2 = 1.558 df = 3 P = 0.669
rs3096140 C 530 0.312 28.2% 42.0% 33.3% 32.1%
T 1168 71.8% 58.0% 66.7% 67.9%
χ2 = 8.048 df = 1 P = 0.005; χ2 = 13.326 df = 3 P = 0.003982
rs2973041 G 217 0.163 18.1% 11.7% 14.6% 14.9%
A 1117 81.9% 88.3% 84.4% 85.1%
χ2 = 3.861 df = 1 P = 0.049; χ2 = 4.554 df = 3 P = 0.208
rs2910702 G 355 0.262 24.5% 32.0% 27.8% 26.9%
A 999 75.5% 68.0% 72.2% 73.1%
χ2 = 2.403 df = 1 P = 0.121; χ2 = 3.538 df = 3 P = 0.316
rs1549250 G 585 0.428 42.9% 44.4% 43.2% 41.3%
T 783 57.1% 55.6% 56.8% 58.7%
χ2 = 0.009 df = 1 P = 0.926; χ2 = 0.399 df = 3 P = 0.940
rs2973050 T 401 0.352 34.6% 41.3% 34.4% 35.3%
C 737 65.4% 58.7% 65.6% 64.7%
χ2 = 0.248 df = 1 P = 0.618; χ2 = 1.658 df = 3 P = 0.646
rs11111 G 216 0.132 14.2% 12.8% 13.7% 9.9%
A 1426 85.8% 87.2% 86.3% 90.1%
χ2 = 1.830 df = 1 P = 0.176; χ2 = 3.864 df = 3 P = 0.277
Signiﬁcant after Bonferroni correction for multiple testing (P < 0.00625) are in bold; dbSNP number, polymorphism identiﬁcation number
in an open-access archive made by the National Center for Biotechnology Information (NCBI) and National Human Genome Research
Institute (NHGRI); MAF, minor allele frequencies; the ﬁrst χ2 test statistics represent analyses between the never smoker and ever smoker
groups; the second χ2 test statistics represent comparison of allele distributions in all four smoking groups.
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the rs3096140 showed a significant association. No signiﬁcant
associations were observed with the other polymorphisms.
The results are summarized in table 2 which shows that the
minor (C) allele of rs3096140 might be a risk factor of life-
time occurrence of smoking behaviour (χ2 = 8.048, df = 1,
P = 0.0046).
Further analyses have been carried out to specify these
associations. Allele frequencies for each of the eight SNPs
were tested among all four categories (never smoked, quit
smoking, occasional smokers and regular smokers) (see
table 2). The rs3096140 SNP showed a significant association
with smoking behaviour (P = 0.003982) which remained
signiﬁcant even after the stringent Bonferroni correction for
multiple testing (Bonferroni 1936; Miller 1981). As summa-
rized in table 2, the rs3096140 minor (C) allele was more
frequent in all three groups who ever smoked: ratio of C
allele were 32.1% among regular smokers, 33.3% among
occasional smokers, and as high as 42.0% among those who
quit smoking. In those who never smoked, frequency of the
C allele was as low as 28.2%. These results show that the
biggest difference in the allele frequency of rs3096140 is
among the never smoker and quitter groups. This result was
supported by 2 × 2 post hoc analyses in the never smoker
versus quit, never smoker versus occasional, never smoker
versus regular smoker groups (ﬁgure 1).
Dimensional association analysis of nicotine addiction
and GDNF polymorphisms
The mean score values of the HONC, as well as that of the
FTND were compared between major and minor allele
carriers of GDNF SNPs by ANCOVA. These questionnaires
were ﬁlled by the occasional and regular smokers only, thus
only these two groups were included in the analyses. Results
are presented in table 3. We observed a nominally signiﬁcant
association between GDNF rs11111 and the level of nicotine
addiction measured by HONC (P = 0.039). The association
showed that the minor allele (G) of rs11111 is a protective
factor against high nicotine addiction level. However, this
result did not remain signiﬁcant after Bonferroni correction
for multiple testing. No signiﬁcant association was found
between the analysed GDNF polymorphisms and nicotine
addiction phenotype measured by FTND.
Smoking, rs3096140 and anxiety
Hospital anxiety and depression scale (HADS) data are
available for most of the participants of the present sample
(N = 800), for details, see Kotyuk et al. (2013a). Possi-
ble interaction effects of smoking behaviour and rs3096140
on anxiety have been tested (ﬁgure 2). HADS anxiety mean
scores of participants possessing any of the rs3096140 alle-
les showed a similar pattern in case of the never smoker,
occasional and regular smoker groups. In these three cases,
anxiety in C allele was somewhat higher as compared to the
T allele. On the other hand, C carriers of the quitter group
showed an opposite pattern. However, two-way ANOVA
did not show any signiﬁcant effects: neither the main effect
of smoking categories (P = 0.071), or the main effect of
rs3096140 (P = 0.170), nor the interaction effect (P =
0.251) was signiﬁcant. These results suggest that association
between smoking behaviour and rs3096140, and associa-
tion between anxiety and rs3096140 are independent. HADS
depression scores have not been analysed due to the ﬂoor
effect characterizing this heathy young adult sample.
Figure 1. Testing the association for smoking initiation: allele frequency of rs3096140
in four groups. 2 × 2 χ2 tests were used to deﬁne allele distribution differences in the
nonconsumer versus quit, nonconsumer versus occasional, nonconsumer versus regular
groups. Rs3096140 T allele frequencies are represented by gray bars, and bars in black
represent the frequencies of rs3096140 C allele.
Journal of Genetics, Vol. 95, No. 4, December 2016 815
Eszter Kotyuk et al.
Table 3. Dimensional analysis: mean scores of HONC and FTND by the alleles of the analysed SNPs.
dbSNP Mean score Mean score
number 2∗N of HONC 2∗N of FTND
rs1981844 C 122 4.60 (±3.2) F(1, 494) = 0.1 79 1.25 (±1.6) F(1, 320) = 1.4
G 376 4.52 (±3.3) P = 0.864 245 1.08 (±1.4) P = 0.240
rs3812047 A 67 4.48 (±2.9) F(1, 572) = 0.4 44 1.25 (±1.4) F(1, 372) = 0.4
G 509 4.72 (±3.3) P = 0.550 332 1.16 (±1.5) P = 0.534
rs3096140 C 206 4.66 (±3.0) F(1, 616) = 0.1 120 1.27 (±1.4) F(1, 384) = 0.2
T 414 4.60 (±3.3) P = 0.865 268 1.19 (±1.5) P = 0.698
rs2973041 G 69 4.17 (±3.2) F(1, 466) = 1.1 45 1.11 (±1.4) F(1, 304) = 0.1
A 401 4.60 (±3.2) P = 0.302 236 1.07 (±1.3) P = 0.859
rs2910702 G 132 4.56 (±3.0) F(1, 472) = 0.1 82 1.16 (±1.4) F(1, 308) = 0.5
A 344 4.56 (±3.3) P = 0.990 230 1.02 (±1.2) P = 0.480
rs1549250 G 202 4.48 (±3.1) F(1, 474) = 0.2 128 1.16 (±1.4) F(1, 312) = 0.9
T 276 4.60 (±3.4) P = 0.672 188 1.01 (±1.2) P = 0.337
rs2973050 T 141 4.73 (±3.2) F(1, 396) = 1.2 95 1.09 (±1.4) F(1, 272) = 0.6
C 259 4.34 (±3.3) P = 0.275 181 0.96 (±1.2) P = 0.448
rs11111 G 67 3.91 (±3.1) F(1, 576) = 4.3 36 0.83 (±1.0) F(1, 370) = 2.6
A 513 4.74 (±3.3) P =0.039 338 1.15 (±1.3) P = 0.110
Nominally signiﬁcant result is in bold.
Figure 2. Effects of smoking behaviour and rs3096140 on anxiety.
Mean HADS anxiety scores in the never (closed circles), quit (open
squares), occasional (open rhombus) and regular groups (open trian-
gles) as a function of rs3096140 C and T alleles. Error bars represent
standard errors of the mean.
Discussion
The presented genetic association analyses were carried out
on a sample of 930 healthy young adults. First, we compared
the allele frequencies of the analysed eight GDNF polymor-
phisms (see table 2) in the four smoking categories. Accord-
ing to the results, there was a signiﬁcant difference in the
allele frequencies in case of rs3096140 (P = 0.0046): the
C allele was more frequent in the smoker groups as com-
pared to the nonsmokers (see ﬁgure 1), suggesting that the
C allele is a risk factor for smoking initiation. Interestingly,
the frequency of the C allele was the highest among smokers
who quit (42%) and somewhat lower in the group of occa-
sional smokers (33.3%) and regular smokers (32.1%). Even
though the difference is more between the never smokers and
quitter groups, it is clear, that the quitter, regular and occasional
smoker groups show the same allele frequency pattern. Thus,
we followed the standard genetic-epidemiological approach
in terms of lifetime occurrence of a behaviour and analysed
the allele frequencies between never and ever smokers. We
suggest that although there were no signiﬁcant difference in
the analysis of never and regular smokers, the result between
never users and lifetime occurrence of smoking behaviour
(created by combining the quitter, occasional and regular cat-
egories) could still have an important impact on the literature
or the genetic background of smoking behaviour, focussing
on lifetime vulnerability of smoking.
We propose that the lack of association between the scales
of nicotine addiction and GDNF rs3096140 also supports
the importance of lifetime occurrence of the behaviour in
genetic association analysis. The lack of association between
rs3096140 and, never and regular smokers, and the lack of
association between rs3096140 and nicotine addiction sug-
gests that the association between rs3096140 and smoking is
not based on the heaviness or ‘regularness’ of this behaviour,
rather based on the vulnerability for smoking (based on the
association between never and ever smoker categories). This
supports the idea, that the association analysis of never–
regular smokers and never–ever smokers are different, imply
different phenotypes.
It seems that this association might not be driven by high
nicotine addiction, rather by some kind of personality traits
which predicts lifetime occurrence of the behaviour, e.g. try-
ing out smoking and quitting. Further investigation of GDNF
rs3096140 and, e.g. novelty seeking or impulsivity would be
needed to clarify this association. We also tested if there is
any association between GDNF polymorphisms and level of
nicotine addiction, but no signiﬁcant results were observed
(see table 3). It is well known that smoking is a very complex
phenotype and even though there are some overlapping
genetic factors of the different aspects, phenotype speciﬁc
genetic risk factors are also plausible. This is in line with
the fact that different aspects of smoking behaviour have
different level of heritability (e.g. Madden et al. 1999). For
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example, it has been demonstrated that the heritability level
of smoking initiation is 56% while the heritability level of
nicotine addiction is 67% suggesting that the genetic vari-
ations that predispose to smoking initiation and to nicotine
dependence have both common and speciﬁc factors (Sullivan
and Kendler 1999).
GDNF is a novel candidate gene in psychiatric genetics,
and there are only a few published association studies avail-
able on schizophrenia (Lee et al. 2001; Michelato et al.
2004; Williams et al. 2007), on attention deﬁcit hyperac-
tivity disorder (Syed et al. 2007; Laurin et al. 2008), on
methamphetamine use (Yoshimura et al. 2011) and on mood
characteristics (Kotyuk et al. 2013a, b). To the best of our
knowledge, no genetic association study has been published
between GDNF polymorphisms and smoking behaviour. On
the other hand, in a Japanese study (Yoshimura et al. 2011) of
GDNF alleles and the severity of methamphetamine use eight
GDNF polymorphisms were analysed. The minor (C) allele
of the rs2910704 SNP was signiﬁcantly more frequent in
those who used only methamphetamine compared to the mul-
tisubstance users. Our results are in line with these ﬁndings
suggesting that variations in the GDNF gene might be related
not only to methamphetamine use but also to smoking.
Regarding smoking and mood disorders, comorbidity is
well supported (Covey et al. 1990; Balfour and Ridley 2000;
Audrain-McGovern et al. 2009). Previously, we observed
an association between GDNF rs3812047, rs3096140 and
anxiety on healthy young adults (Kotyuk et al. 2013a) and
we replicated the effect of rs3812047 on anxiety on a sam-
ple of bipolar depressive patients (Kotyuk et al. 2013b). On
the sample of healthy young adults we demonstrated that
the C allele of rs3096140 is a risk factor for higher anxi-
ety level. The very same genetic factor was shown here as
a risk factor for smoking. However, we did not ﬁnd a sig-
niﬁcant interaction effect of rs3096140 and smoking cate-
gories on anxiety. Taken together, these results suggest that
GDNF polymorphisms may have a crucial role in numerous
neuropsychological diseases. Further investigation of GDNF
gene variants and psychiatric diseases are needed to clarify
these associations.
One of the limitations of the presented study is the rela-
tively low sample size, especially in some of the smoking
categories. It would also be desirable to repeat the present
ﬁndings on a sample that is age matched and have same
number of participants in each smoking group. Also, as in
any self-report study, self-classiﬁcation could lead to some
limitations. For example, the similarities between rs3096140
allele distributions by the occasional and regular smokers
might be unexpected. However, it is probably due to sample
characteristics. The present sample mainly contains young
healthy adults recruited at different Hungarian educational
institutions, and the selection criteria included age range
between 18 and 35 years. In this age population, it is possi-
ble that participants report themselves as occasional smokers
at the time of data collection, even though they will not stay
occasional smokers, and probably continue their smoking
career and become regular smokers in time. This is also sup-
ported by the number of occasional smokers in the present
sample (N = 163). It would be really hard to ﬁnd this many
true occasional smokers. However, in case of the standard
genetic-epidemiological analysis this did not cause any dis-
tortions. In any case, repetition of the present analyses on
independent samples is necessary. Further, there is a possibil-
ity for false positive results, although Bonferroni correction
for multiple testing was used to avoid this.
In sum, the present study demonstrated an association
between rs3096140 and smoking behaviour, suggesting that
the T allele might be a risk factor for lifetime occurrence
of smoking. However, further analysis is needed to clarify
the possible relationship between GDNF polymorphisms and
addictions, addictions and the possible moderating factors,
such as anxiety.
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